Reflections

In the high-stakes world of biotechnology, success often seems to hinge on a single, defining goal: securing regulatory approval. For many biopharma leaders, finally receiving that green light from agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) is a cause for celebration—and rightfully so. It represents years…

We are pleased to share the results of our recent validation study, “Loon Lens 1.0 Validation: Agentic AI for Title and Abstract Screening in Systematic Literature Reviews,” now available on medRxiv. This study evaluates the effectiveness of Loon Lens™, our autonomous AI literature screener designed to automate the Title and Abstract (TiAb) screening process in…

In this article, we navigate NICE’s Position on the Use of AI in Evidence Generation for Health Technology Assessment (HTA) and explain how Loon Hatch™ – our end-to-end, fully automated, and expert-validated evidence synthesis solution – and Loon Lens™ – our scientifically validated, autonomous literature screener – align with the HTA body’s’ guidelines on the…